Symbols

TMCI

Treace Medical·NASDAQ

--(--)

TMCI fundamentals

TMCI Q4 2025 Earnings

Treace Medical (TMCI) released its earnings on Feb 27, 2026: revenue was 61.82M (YoY -10.03%), missed estimates; EPS was -0.1503 (YoY -1403.00%), beat estimates.

Revenue / YoY

61.82M

-10.03%

EPS / YoY

-0.1503

-1403.00%

Report date

Feb 27, 2026

TMCI Earnings Call Summary for Q4,2025

2026 Revenue Outlook: $200M-$212M (-6% to 0% YoY), with Q4 growth from new product launches and case volume acceleration.
Product Expansion: 5 new systems cover 100% of bunion procedures; 25% of surgeons adopted new systems within 2 quarters.
Cash Burn Reduction: Target 50% reduction to $13.6M in 2026, supported by $115M credit facility.
TAM Expansion: $300M adjacencies (mid-foot fusion, MTP fusion) with 2026 product launches (SuperBite, Speed XM).
Profitability Improvement: Adjusted EBITDA loss narrows to $4M-$6M in 2026, from $(3.9M) in 2025.

Earnings

EPS

Revenue

Revenue & Expenses

TMCI has released its 2025 Q4 earnings report, with revenue of 62.52M, reflecting a YoY change of -9.01%, and net profit of -9.39M, showing a YoY change of -1775.05%. The Sankey diagram below clearly presents TMCI's revenue sources and cost distribution.

Key Indicators

Treace Medical (TMCI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Treace Medical (TMCI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Treace Medical (TMCI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Treace Medical (TMCI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown